CancerSarcomaLeukaemiaBreast Cancer (Locally Advanced or Metastatic)Lung Cancer (Diagnosis)Colorectal CancerMelanoma (Skin Cancer)Bladder CancerKidney CancerPancreatic Cancer MetastaticLiver Cancer (Primary and Metastatic)Ovarian CancerEsophageal CancerGlioblastomaNon-Melanoma Skin Cancer
EBNK-001 + IL-15 + Pembrolizumab: Biological: EBNK-001 (Allogeneic NK Cells) Dose levels (example): 1×10\^8; 3×10\^8; 9×10\^8 viable cells/infusion Schedule: weekly infusions on Days 1, 8, and 15 (per cycle)
Drug: Cyclophosphamide (CY) lymphodepletion: 300 mg/m² IV daily ×2 days (Cycle 1 only) Drug: Fludarabine (FLU)
Example lymphodepletion: 25 mg/m² IV daily ×2 days (Cycle 1 only) Drug: Interleukin-15 (IL-15) Low-dose IL-15 given after NK cell infusion to support NK cell survival dose used in NK protocols: 6 MIU per dose
Drug: Pembrolizumab Pembrolizumab administered per standard prescribing schedule
Study summary
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide/fludarabine (CY/FLU) and supported with low-dose IL-15, administered either alone or in combination with pembrolizumab in adults with advanced/metastatic solid tumors. The study will determine a recommended Phase 2 dose (RP2D) and explore signals of clinical activity using RECIST-based response criteria.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥18 years.
* Histologically confirmed advanced/metastatic solid tumor that is relapsed/refractory after standard therapy (or no standard therapy available).
* Measurable disease per RECIST v1.1 (or iRECIST if applicable).
* ECOG performance status 0-1 (or 0-2 as allowed).
* Adequate organ function (thresholds modeled on NK protocols):
* Platelets ≥ 75,000/µL; hemoglobin ≥ 9 g/dL; ANC ≥ 1,000/µL (unsupported by growth factors/transfusions as defined).
* eGFR ≥ 60 mL/min/1.73m².
* AST/ALT ≤ 3× ULN.
* Oxygen saturation ≥ 90% on room air (with PFT requirements if indicated).
* LVEF ≥ 40% (by ECHO/MUGA/CMR).
* If brain metastases are present, they must be stable for a defined period (example: ≥3 months) and not requiring escalating steroids.
Exclusion Criteria:
* Pregnant or breastfeeding.
* Any condition requiring systemic immunosuppression (e.g., \>5 mg prednisone/day or equivalent) during dosing window (topical/inhaled may be allowed).
* Active autoimmune disease requiring systemic immunosuppression.
* Uncontrolled bacterial, fungal, or viral infection.
* Receipt of investigational agent within 28 days before first study drug.
* Live vaccine within 6 weeks prior to lymphodepletion.
* Known HIV positivity or active hepatitis B/C with detectable viral load (protocol may allow chronic asymptomatic hepatitis depending on risk plan).
* Known allergy to investigational product components (example: albumin/human or DMSO).
* Any medical/social condition likely to interfere with study compliance or increase risk.
Primary outcome measure(s)
Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) — 30 DAYS
Incidence of Dose-Limiting Toxicities (DLTs) — 30 DAYS Incidence of Dose-Limiting Toxicities (DLTs)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.